相关实验视频

Updated: Jul 27, 2025

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
07:55

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP

Published on: October 17, 2015

11.9K

PCP4通过影响粉样β蛋白前体处理促进阿尔茨海默病的发病

Dongjie Hu1, Xiangjun Dong1, Qunxian Wang1

  • 1Chongqing Key Laboratory of Translational Medical Research in Cognitive Development and Learning and Memory Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China.

Journal of Alzheimer's disease : JAD
|June 11, 2023
PubMed
概括

普尔金尼细胞蛋白4 (PCP4) 通过影响粉样β蛋白前体 (AβPP) 处理,促进阿尔茨海默病 (AD) 的进展. 这项研究强调PCP4作为潜在的治疗点,通过影响Aβ病理.

关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.唐氏综合征是什么意思 唐氏综合征普尔金耶细胞蛋白4 普尔金耶细胞蛋白4粉样蛋白-β-β 的存在.氨基酸β蛋白质前体的前体.

更多相关视频

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model06:02

Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model

Published on: July 26, 2011

36.8K
A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse08:08

A Technique for Serial Collection of Cerebrospinal Fluid from the Cisterna Magna in Mouse

Published on: November 10, 2008

102.1K

相关概念视频

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.6K